On May 3-4, 2016, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored the Consultation on Global Trends of HIV Drug Resistance in Rockville, MD. The goals of the conference were to identify research gaps for HIV Drug Resistance (HIVDR) in low and middle income countries (LMIC) and to develop collaborations between key members of academia, government, industry, and non-profit organizations to address these gaps through an actionable plan.
Please see below for the agenda and the PowerPoint presentations shared at the conference.
Opening Remarks
Anthony S. Fauci, MD - National Institute of Allergy and Infectious Diseases, NIH
Addressing HIVDR to Reach 90-90-90: What Do We Know and What Do We Need to Do?
Silvia Bertagnolio, MD - World Health Organization
PEPFAR Priorities & HIV Drug Resistance: Where Are We Heading and What Has Us Worried
Elliot Raizes, MD - Division of Global HIV & TB, CDC Center for Global Health
Global Drug Resistance Following ART Scale Up
Ravindra K. Gupta, MD - Wellcome Trust, University College London
High Rates of HIVDR Complicate ART Choices for Children and Adolescents
George K. Siberry, MD, MPH - Office of the U.S. Global AIDS Coordinator
Can We Use Sequential Regimens In Lieu of HIV Drug Resistance Testing?
MA Boyd, MD, FRACP - The Kirby Institute, University of New South Wales
Not All Drug Regimens Are Created Equal
Mark A. Wainberg - McGill University AIDS Centre, Jewish General Hospital
Use of Modeling to Inform Policy on Responding to Potential Future High Levels of Pre-treatment Drug Resistance
Andrew Phillips, University College London
New Technologies for HIVDR Testing:Next Generation Sequencing for HIVDR
Christos Petropolous, PhD - Monogram Biosciences
New Assays for HIVDR: Implications for Point-of-Care Testing
Lisa M. Frenkel, MD - University of Washington and Seattle Children's Hospital
Dried Blood Spots and Other Sample Types for HIVDR Testing
Deborah Persaud, MD - Johns Hopkins University School of Medicine & Bloomberg School of Public Health
HIV Drug Resistance: New Mutations and Cross Resistance
Bob Shafer, MD - Stanford University
Are Minor Variants Important?
Jonathan Li, MD - Brigham and Women's Hospital & Harvard Medical School
Does Subtype Matter?
Carole Wallis, PhD - Lancet Laboratories
ART Resistance and DR Testing in India
Dr. N. Kumarasamy - YRGCARE Medical Centre
Economics of Drug Resistance Testing
Emily P. Hyle, MD, SM - Massachusetts General Hospital & Medical Practice Evaluation Center
Lessons Learned from Scale-Up of Viral Load Testing in LMIC: Could Viral Load Testing Be Harnessed to Help Reduce HIVDR?
Steven J. Reynolds, MD, MPH - Section on International HIV/STD Research, NIAID/NIH ICER Program Uganda
Challenges with HIVDR Testing in a Real-World LMIC Setting
Dr. Arlene Chua - Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital
ACTG/IMPAACT BRI Specimen Repository: The "IDEA GENERATOR"
Bob Coombs, MD, PhD - University of Washington
Monitoring HIV Drug Resistance in Africa and Asia: Pan-African (PASER) and TREAT Asia (TASER) Studies to Evaluate Resistance
Raph Hamers, MD, PhD - Academic Medical Center of the University of Amsterdam, Amsterdam Institute for the Global Health and Development
Please click here for additional information on the National Institute of Allergy and Infectious Diseases (NIAID).